The ASPP2 (Apoptosis-Stimulating Protein of p53 2) antibody is a crucial tool for studying the ASPP family of proteins, which regulate apoptosis and cellular stress responses. ASPP2. encoded by the TP53BP2 gene, is a key regulatory protein that enhances the pro-apoptotic activity of p53 by selectively promoting the transcription of apoptosis-inducing genes over cell-cycle arrest genes. It interacts with p53 through its SH3 domain and ankyrin repeats, facilitating p53’s binding to target promoters. ASPP2 also engages with other proteins, such as Bcl-2 and NF-κB, expanding its role in apoptosis, DNA repair, and cell polarity. Dysregulation of ASPP2 is linked to cancer progression, as its loss or downregulation is observed in tumors, correlating with poor prognosis and chemoresistance.
ASPP2 antibodies are widely used in research to detect ASPP2 expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate ASPP2’s subcellular localization, interactions, and tissue-specific expression patterns. Validated antibodies often undergo specificity testing using knockout cell lines or siRNA-mediated knockdown. Researchers utilize ASPP2 antibodies to explore its tumor-suppressive functions, roles in developmental biology, and potential therapeutic targeting. Commercial ASPP2 antibodies vary in clonality (monoclonal/polyclonal), host species (rabbit, mouse), and epitope recognition, necessitating careful selection based on experimental needs. Their application advances understanding of p53 signaling networks and cancer mechanisms.